The Conversation: Data suggest no increased risk of blood clots from the AstraZeneca vaccine. Australia shouldn’t pause its rollout

With some European countries opting to pause the rollout of COVID-19 AstraZeneca in response to reports of blood clots, Australian experts have cautioned against any pauses whilst investigations are underway.

Thromboembolic events occur in approximately 17,000 Australians per year. In a global vaccine rollout it is therefore expected that some people will develop a blood clot coincidentally after they have received the vaccine. This does not meant that the vaccine caused it.

Since COVID-19 AstraZeneca vaccinations began, there have been 30 thromboembolic events reported (as of March 10, 2021) in approximately 5 million vaccine recipients. This is lower than the natural rate expected to occur.

All adverse events must be thoroughly investigated. The robust safety surveillance systems in Australia are established to effectively identify any signals requiring follow up. Extreme caution is urged when considering a pause in rollout while investigations are underway as this can damage vaccine confidence.

To read more, please read the article below:

The Conversation: Data suggest no increased risk of blood clots from the AstraZeneca vaccine. Australia shouldn’t pause its rollout

 

 

 

 


The bmj: Covid-19: Booster dose will be needed in autumn to avoid winter surge, says government adviser

Anthony Harnden, Deputy Chair of the Joint Committee on Vaccination and Immunisation (JCVI) in the UK, has suggested that booster doses of COVID-19 vaccines are likely to be required.

With minimal data surrounding the duration of protection provided by COVID-19 vaccines and the emergence of new strain variants, the UK is considering commencing booster doses from August of this year.

Để đọc thêm theo liên kết dưới đây:

The bmj: Covid-19: Booster dose will be needed in autumn to avoid winter surge, says government adviser

 


A recording of the March CVU mini is now available

Cảm ơn tất cả những người đã tham dự sự kiện miniseries CVU gần đây của chúng tôi COVID-19 vaccines: Engagement, Communication and Safety on 9th March 2021.

Presentation topics included COVID-19 vaccine stakeholder engagement and participation, vaccine communication and hesitancy, and an update on the Victorian Specialist Immunisation Service (VicSIS) and international vaccine safety.

MỘT miễn phí ghi lại sự kiện này hiện có sẵn thông qua cổng thông tin giáo dục của chúng tôi.

Để truy cập bản ghi này, vui lòng theo liên kết bên dưới:

CVU mini - 9th March 2021


The Guardian: Israel says 600 children given Covid jab had no serious side-effects

Following an expansion of Israel's COVID-19 vaccination program, around 600 children (≥ 12 years) have received the Pfizer/BioNTech COVID-19 vaccine. Reported side-effects in this age group have been minor and the vaccine has been well tolerated.

Due to the emergence of more transmissible strains of COVID-19, experts have now suggested that in order to achieve herd immunity closer to 90% coverage will be required. In a population of 9 million people, with approximately 1/4 of those aged under 16 years, lowering the age limit for COVID-19 vaccination is an important development for Israel.

Để đọc thêm theo liên kết dưới đây:

The Guardian: Israel says 600 children given Covid jab had no serious side-effects


TGA: Vắc xin AstraZeneca ChAdOx1-S COVID-19

Denmark, Iceland and Norway have temporarily paused the distribution of COVID-19 AstraZeneca as a precautionary measure in response to reports of blood clots following immunisation (including 1 death in Denmark). The European Medicines Agency's safety committee is conducting a rapid review into the events.

The Therapeutic Goods Administration (TGA) have advised that a link has not been confirmed and to date there have been no reports of similar events in Australia. Extensive international vaccination programs have not indicated an increased risk of blood clots associated with the vaccine.

Vaccination with COVID-19 AstraZeneca continues in other countries including the United Kingdom and France.

Please refer to the full alert below for more information:

TGA: Vắc xin AstraZeneca ChAdOx1-S COVID-19


Save the date for our April CVU mini event: Monday 12 April 2021

MVEC invites you to Save the Date for our next CVU mini!

Ngày: Monday 12 April, 2021
Thời gian: 7:00pm - 8:30pm AEST

Thông tin chi tiết và thông tin đăng ký sẽ sớm có trên trang sự kiệnCổng thông tin giáo dục.

Để cập nhật những tin tức mới nhất của chúng tôi, bao gồm các sự kiện sắp tới, bạn có thể đăng ký kênh của chúng tôi bản tin hàng tuần.


Additional module added to Victorian COVID-19 eLearning Competency

An additional module titled Preparing Comirnaty™ (Pfizer BNT162b2) COVID-19 Vaccine has been added to the Victorian COVID-19 eLearning Competency.

Please note the advice contained in this module is specific to the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty™).

If you have already completed the Victorian COVID-19 eLearning Competency you can login and access this additional module via your profile in the Cổng giáo dục MVEC.

 


Swollen Lymph Nodes Under Armpit After COVID-19 Vaccine May Mimic Breast Cancer Symptoms

The Society of Breast Imaging (SBI) in the United States is recommending women wait at least four weeks after receiving a COVID-19 vaccine to schedule a mammogram due to the potential side-effect of swollen or tender lymph nodes in the armpit. Changes in the lymph nodes can be a sign of breast cancer and the concerns are this could lead to false readings on mammograms leading to further unnecessary testing.

This advice was issued based on the rates of swelling and tenderness in the lymph nodes post the Moderna COVID-19 vaccine and Pfizer BioNTech COVID-19 vaccine in the United States. Whilst rare in people who have received the Pfizer BioNTech vaccine (which is currently provisionally registered for use in Australia), the SBI notes the incidence rates are most likely higher than reported and accordingly issued the aforementioned advice to separate mammograms from COVID-19 vaccines by four to six weeks.

Đọc thêm qua liên kết dưới đây:

Health online: Swollen Lymph Nodes Under Armpit After COVID-19 Vaccine May Mimic Breast Cancer Symptoms—Here’s What to Know


Incidents after vaccination with AstraZeneca's COVID-19 vaccine

Following reports of 2 temporally associated severe adverse events following immunisation (AEFI), các Austrian Federal Office for Safety in Health Care (the national regulatory body for medicines) have halted the supply and distribution of a specific batch of COVID-19 AstraZeneca.

It is important to note that data from clinical trials shows no evidence of a casual relationship and this halt is being utilised as a precautionary measure only. An immediate review of international reports of similar AEFI show no signals for concern. Vaccine rollout using alternate batches of COVID-19 AstraZeneca continues and further investigations are ongoing.

 To read the official announcement follow the link below:

Austrian Federal Office for Safety in Health Care: Incidents after vaccination with AstraZeneca's COVID-19 vaccine


Rút kinh nghiệm từ những sai sót với vắc xin COVID-19 mới

Vào tháng 12 năm 2020, vắc xin COVID-19 bắt đầu được triển khai trên khắp Hoa Kỳ. Bài báo này được xuất bản bởi Viện Thực hành Thuốc An toàn, thảo luận về các báo cáo khác nhau về các lỗi chuẩn bị và quản lý đã xảy ra kể từ khi bắt đầu triển khai.

Với phạm vi của chiến dịch tiêm chủng COVID-19 toàn cầu, dự kiến sẽ có những sai sót. Khi Úc bắt đầu triển khai trên toàn quốc, một bài học quan trọng là đảm bảo rằng tất cả các sai sót và phản ứng bất lợi của vắc xin COVID-19 đều được báo cáo cho các cơ quan hữu quan để giúp ngăn chặn những loại sai sót này xảy ra tại đây.

Để đọc thêm theo liên kết dưới đây:

ISMP: Rút kinh nghiệm từ những sai sót với vắc xin COVID-19 mới